8-K: Pulse Biosciences Announces Successful First-in-Human Treatment with Nano-PFA Cardiac Surgery System

Pulse Biosciences reports successful treatment of the first two patients in a feasibility study using its novel Cardiac Surgery System for atrial fibrillation, and enrollment in the FDA's TAP program.

Summary

• Pulse Biosciences has successfully treated two patients in a first-in-human feasibility study using their Cardiac Surgery System for atrial fibrillation.
• The study is a multicenter trial involving up to 30 patients and includes a three-month follow-up to confirm chronic isolation.
• The company's nano-PFA Cardiac Surgical System has also been enrolled in the FDA's Total Product Life Cycle (TPLC) Advisory Program (TAP).
• The TAP program aims to accelerate the development of innovative medical devices by providing early and frequent communication with the FDA.
• The initial procedures showed effective pulmonary vein and box isolation using the Pulse Biosciences system.
• The system is designed to produce durable, continuous, transmural ablation lesions during cardiac surgery.
• Pre-clinical studies suggest a single application of less than two seconds with the Surgical Clamp creates a consistent, transmural, durable ablation, which is significantly faster than current thermal ablation technologies.
• The nano-PFA technology is non-thermal, reducing the risk of injury to surrounding tissues compared to thermal radiofrequency ablation.
• The company plans to submit for IDE approval from the FDA to begin U.S. clinical work.
• Pulse Biosciences intends to begin its pivotal clinical study in early 2025 and will provide further details later this year.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful initial human trials and the enrollment in the FDA's TAP program. The technology's potential to be faster and safer than current methods also contributes to the positive outlook.

Positives

• Successful treatment of the first two patients in a human study indicates the potential of the technology.
• Enrollment in the FDA's TAP program could expedite the regulatory approval process.
• The nano-PFA technology offers a faster and potentially safer alternative to current thermal ablation methods.
• The initial procedure results showed effective pulmonary vein and box isolation.
• The device's intuitive design facilitates an efficient procedure where surgeons can create controlled lesions with adequate depth very rapidly.
• The patients tolerated the procedure well.

Risks

• The technology is still in early stages of clinical trials, and further studies are needed to confirm safety and efficacy.
• Regulatory approval is not guaranteed, and the process can be lengthy and costly.
• The company's plans to begin a pivotal clinical study in early 2025 are subject to change.
• The company's success depends on the ability to commercialize its technology and gain market acceptance.

Future Outlook

The company plans to submit for IDE approval from the FDA to begin U.S. clinical work and intends to begin its pivotal clinical study in early 2025, with further details to be provided later this year. The company also plans to pursue FDA premarket approval (PMA) to commercialize its nano-PFA Cardiac Surgical System in the United States as a treatment for atrial fibrillation.

Management Comments

• 'The initial procedure results showed effective pulmonary vein and box isolation with Pulses Cardiac Surgery System,' said Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital.
• 'We were impressed by how rapidly and effectively we were able to produce linear ablations in a fraction of the time it takes with the current thermal modalities we use, such as radiofrequency or cryoablation,' added Dr. Van Putte.
• 'These initial treatment results confirm our preclinical work with the cardiac surgical system,' said Dr. Gan Dunnington, Chief Medical Officer, Cardiac Surgery of Pulse Biosciences.
• 'We are pleased to see how the intuitive design of the device facilitates an efficient procedure where surgeons can create controlled lesions with adequate depth very rapidly,' added Dr. Dunnington.
• 'We continue to make great strides on the development of our current nano-PFA devices, three of which have now been used in patients with initial promising results,' stated President and Chief Executive Officer Burke T. Barrett.
• 'These initial clinical results with the Cardiac Surgical System will inform the next steps of our clinical and regulatory strategy,' added Burke T. Barrett.

Industry Context

This announcement is significant in the context of the medical device industry, particularly in the field of cardiac surgery and atrial fibrillation treatment. The development of a faster and potentially safer ablation technology could disrupt the market currently dominated by thermal ablation methods like radiofrequency and cryoablation. The FDA's TAP program enrollment also highlights the potential of this technology to address unmet medical needs.

Comparison to Industry Standards

• Current thermal ablation technologies, such as radiofrequency and cryoablation, typically require longer procedure times compared to the less than two seconds per application reported for Pulse Biosciences' nano-PFA technology.
• Companies like Medtronic and Abbott are major players in the cardiac ablation market, but Pulse Biosciences' non-thermal approach could offer a competitive advantage by reducing the risk of thermal damage to surrounding tissues.
• The FDA's TAP program is designed to accelerate the development of innovative medical devices, and the enrollment of Pulse Biosciences' system suggests that the FDA sees potential in this technology.
• The company's claim of one-twentieth the time compared to current thermal ablation technologies is a significant improvement if proven in larger studies.

Stakeholder Impact

• Shareholders may view this announcement positively due to the potential for future revenue and market growth.
• Employees may be motivated by the progress of the company's technology.
• Patients with atrial fibrillation may benefit from a new, potentially safer and more effective treatment option.
• Clinicians may be interested in adopting this new technology for their practice.
• Suppliers and creditors may see this as a positive development for the company's future.

Next Steps

• The company intends to continue enrollment in the feasibility clinical study.
• Pulse Biosciences plans to submit for IDE approval from the FDA to begin U.S. clinical work.
• The company intends to begin its pivotal clinical study in early 2025.
• The company will provide additional details on the study and its regulatory and commercial implications later this year.
• The company plans to pursue FDA premarket approval (PMA) to commercialize its nano-PFA Cardiac Surgical System in the United States.

Key Dates

Keywords

atrial fibrillation, nano-PFA, cardiac surgery, ablation, FDA, TAP program, clinical study, medical device, CellFX, nsPFA